Morgan Stanley analyst Michael Ulz sets a bullish price target of $105 for Viking Therapeutics, indicating a potential upside of approximately 78.43%.
VKTX’s stock experienced a slight dip, closing at $47.39, amidst an overall market uptick.
The company’s stock has been volatile, with a significant range over the past year, highlighting the risks and opportunities in the biopharmaceutical sector.

Michael Ulz of Morgan Stanley has recently set a bullish price target of $105 for Viking Therapeutics (NASDAQ:VKTX), suggesting a significant potential upside of approximately 78.43% from its current trading price of $47.39. This optimistic forecast, published on June 27, 2024, underscores the analyst’s confidence in VKTX’s growth prospects. Viking Therapeutics is a biopharmaceutical company focused on the development of therapies for metabolic and endocrine disorders, operating in a competitive sector where innovation and clinical trial outcomes can greatly influence stock performance.
Despite the bullish outlook from Morgan Stanley, VKTX experienced a slight dip in its stock price, closing at $47.39, which is a decrease of 0.86% from the previous trading session. This decline occurred in the context of an overall market uptick, making VKTX’s performance notably contrasting. Such movements are not uncommon in the biopharmaceutical sector, where stock prices can be highly volatile, reacting to both market sentiments and company-specific news.
The trading activity for VKTX on the NASDAQ saw its price fluctuate between a low of $46.11 and a high of $47.9799 during the day. Over the past year, the company’s stock has seen a significant range, hitting a low of $8.28 and a high of $99.41. This volatility reflects the inherent risks and opportunities within the biopharmaceutical industry, where successful drug development can lead to substantial rewards while setbacks can cause sharp declines.
With a market capitalization of about $5.23 billion and a trading volume of 2.8 million shares, VKTX stands as a notable player in its sector. The company’s performance and the optimistic price target set by Michael Ulz of Morgan Stanley highlight the potential for growth, despite the recent dip in stock price. Investors and analysts alike will be closely watching VKTX’s progress, especially in its drug development pipeline, to see if it can achieve the lofty expectations set by its bullish forecasts.